[go: up one dir, main page]

NO20076691L - Nanopartikulaere imatinib-mesylatformuleringer - Google Patents

Nanopartikulaere imatinib-mesylatformuleringer

Info

Publication number
NO20076691L
NO20076691L NO20076691A NO20076691A NO20076691L NO 20076691 L NO20076691 L NO 20076691L NO 20076691 A NO20076691 A NO 20076691A NO 20076691 A NO20076691 A NO 20076691A NO 20076691 L NO20076691 L NO 20076691L
Authority
NO
Norway
Prior art keywords
imatinib mesylate
nanoparticulate
composition
nanoparticulate imatinib
mesylate formulations
Prior art date
Application number
NO20076691A
Other languages
English (en)
Norwegian (no)
Inventor
Scott Jenkins
Gary G Liversidge
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20076691L publication Critical patent/NO20076691L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20076691A 2005-06-03 2007-12-28 Nanopartikulaere imatinib-mesylatformuleringer NO20076691L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68714605P 2005-06-03 2005-06-03
PCT/US2006/021657 WO2006133046A2 (fr) 2005-06-03 2006-06-05 Formulations d'imatinib mesylate nanoparticulaires

Publications (1)

Publication Number Publication Date
NO20076691L true NO20076691L (no) 2008-02-25

Family

ID=37498974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076691A NO20076691L (no) 2005-06-03 2007-12-28 Nanopartikulaere imatinib-mesylatformuleringer

Country Status (17)

Country Link
US (1) US20060275372A1 (fr)
EP (1) EP1895984B8 (fr)
JP (1) JP2008542397A (fr)
KR (1) KR20080017067A (fr)
CN (1) CN101232870A (fr)
AT (1) ATE459341T1 (fr)
AU (1) AU2006255177A1 (fr)
BR (1) BRPI0613540A2 (fr)
CA (1) CA2610448A1 (fr)
DE (1) DE602006012671D1 (fr)
EA (2) EA015102B1 (fr)
ES (1) ES2341996T3 (fr)
IL (1) IL187841A0 (fr)
MX (1) MX2007015309A (fr)
NO (1) NO20076691L (fr)
WO (1) WO2006133046A2 (fr)
ZA (1) ZA200710763B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0602338A (pt) * 2006-03-24 2007-12-11 Univ Kyushu Nat Univ Corp compostos orgánicos
US20060223817A1 (en) * 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
EP2343053A1 (fr) 2006-05-30 2011-07-13 Elan Pharma International Limited Compositions de posaconazole nanoparticulaire
US20090324718A1 (en) * 2006-09-01 2009-12-31 Ilan Zalit Imatinib compositions
US8466154B2 (en) 2006-10-27 2013-06-18 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
EP1920767A1 (fr) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Forme posologique d'Imatinib préparée à l'état fondu.
US20080293648A1 (en) * 2007-01-05 2008-11-27 Saha Pharmaceuticals, Inc. Compositions and Methods for Cancer Treatment
EP2120877A2 (fr) * 2007-03-12 2009-11-25 Dr. Reddy's Laboratories Ltd. Mésylate d'imatinib
US20080234286A1 (en) * 2007-03-20 2008-09-25 Chemagis Ltd. Stable amorphous imatinib mesylate and production process therefor
AU2012201613B2 (en) * 2007-06-07 2014-12-04 Novartis Ag Stabilized amorphous forms of Imatinib mesylate
DK2305263T3 (da) * 2007-06-07 2012-10-22 Novartis Ag Stabiliserede amorfe former af imatinibmesylat
EP2081556A1 (fr) * 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Compositions d'imatinib stables
ITRM20080684A1 (it) * 2008-12-19 2010-06-20 Giovanni Cesareni Uso di inibitori della tirosin chinasi c-abl per la preservazione degli oociti.
EP3167875A1 (fr) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Réduction d'agrégation de type paillettes dans des compositions de meloxicam nanoparticulaire
WO2011161689A1 (fr) * 2010-06-21 2011-12-29 Suven Nishtaa Pharma Pvt Ltd Comprimé pharmaceutique de mésylate d'imatinib
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
US9750700B2 (en) * 2011-06-22 2017-09-05 Natco Pharma Limited Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
WO2013008253A2 (fr) * 2011-07-11 2013-01-17 Dr. Reddys Laboratories Limited Formulations d'imatinib
US20150125534A1 (en) * 2011-11-24 2015-05-07 Imuneks Farma Ilac Sanayi Ve Ticaret A.S. Imatinib solid dosage forms reconstituted just before use
SG11201405099UA (en) 2012-02-21 2014-10-30 Ranbaxy Lab Ltd Stable dosage forms of imatinib mesylate
RU2517216C2 (ru) * 2012-08-22 2014-05-27 Закрытое Акционерное Общество "БИОКАД" (ЗАО "БИОКАД") Фармацевтическая композиция иматиниба или его фармацевтически приемлемой соли, способ ее получения и способ(ы) лечения
EP2749269A1 (fr) * 2012-12-31 2014-07-02 Deva Holding Anonim Sirketi Procédé pour la préparation d'adsorbés de imatinib
KR20150123838A (ko) * 2013-03-04 2015-11-04 브이티브이 테라퓨틱스 엘엘씨 안정한 글루코키나제 활성화제 조성물
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
EA029062B9 (ru) * 2013-09-20 2018-05-31 Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции и продукт способа
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
CN104739785A (zh) * 2013-12-25 2015-07-01 辰欣药业股份有限公司 一种具高溶出行为的甲磺酸伊马替尼片的组成及制备方法
CN106856249B (zh) * 2016-12-19 2019-07-09 河南超威电源有限公司 一种以阿拉伯胶作为稳定剂制备胶体电解液的方法
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
RU2020108342A (ru) 2017-07-26 2021-08-26 Эф Тэ Эф Фарма Привейт Лимитед Жидкие дозируемые лекарственные формы иматиниба
CN108904809A (zh) * 2018-08-20 2018-11-30 黎庆有 一种靶向抗肿瘤药物
CN110664757B (zh) * 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
JP2022532431A (ja) 2019-05-16 2022-07-14 エアロベイト セラピューティクス， インコーポレイテッド イマチニブ製剤、その製造および使用
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
CN118986905B (zh) * 2024-08-14 2025-04-29 郑州大学第一附属医院 一种甲磺酸阿帕替尼片及其制备方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) * 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
EP0458894B1 (fr) * 1989-02-17 1996-05-15 The Liposome Company, Inc. Excipient lipidique pour administration par voie nasale et autres applications locales
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
JPH06511481A (ja) * 1991-07-05 1994-12-22 ユニバーシティ オブ ロチェスター 気泡を取り込む超微小非凝集多孔質粒子
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) * 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) * 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
EP0723965B1 (fr) * 1993-09-29 2001-05-30 Meiji Seika Kaisha Ltd. Nouveaux derives de cephalosporine
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5525328A (en) * 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5500204A (en) * 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
EP0810853B1 (fr) * 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols contenant des dispersions de nanoparticules
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5643552A (en) * 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) * 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) * 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
WO1998035666A1 (fr) * 1997-02-13 1998-08-20 Nanosystems Llc Preparation de pastilles de naproxene nanoparticulaire
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
EP1128858A1 (fr) * 1998-11-13 2001-09-05 Elan Pharma International Limited Administration de medicament et systeme a cet effet
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
JP4156807B2 (ja) * 1999-06-01 2008-09-24 エラン ファーマ インターナショナル，リミティド 小型ミル及びその方法
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040026546A1 (en) * 2000-04-26 2004-02-12 Czekai David A Apparatus for sanitary wet milling
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
DE60227802D1 (de) * 2001-06-05 2008-09-04 Elan Pharma Int Ltd Mahlvorrichtung und verfahren zu deren betrieb
US20030087308A1 (en) * 2001-06-22 2003-05-08 Elan Pharma International Limited Method for high through put screening using a small scale mill or microfluidics
ES2280582T3 (es) * 2001-09-19 2007-09-16 Elan Pharma International Limited Formulaciones de insulina en nanoparticulas.
DE60222160T2 (de) * 2001-10-12 2008-06-12 Elan Pharma International Ltd., Athlone Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
AU2003230692A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of map kinase inhibitors
DE60309300T3 (de) * 2002-03-20 2011-02-24 Elan Pharma International Ltd. Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
DE60325718D1 (de) * 2002-05-06 2009-02-26 Elan Pharma Int Ltd Nystatin-nanopartikelzusammensetzungen
JP2005531606A (ja) * 2002-06-10 2005-10-20 エラン ファーマ インターナショナル，リミティド ナノ粒子ステロール製剤およびステロールの組合せ
RU2342931C2 (ru) * 2002-08-20 2009-01-10 Бристол-Маерс Сквибб Компани Состав на основе комплекса арипипразола
CA2498207C (fr) * 2002-09-11 2012-03-13 Elan Pharma International Ltd. Compositions d'agents actifs nanoparticulaires stabilisees sous forme de gel
WO2004024126A1 (fr) * 2002-09-13 2004-03-25 Cydex, Inc. Capsules contenant des compositions de remplissage aqueux stabilisees avec une cyclodextrine derivee
US20040127571A1 (en) * 2002-09-19 2004-07-01 University Of South Florida Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate
CA2500908A1 (fr) * 2002-10-04 2004-04-22 Elan Pharma International Limited Irradiation gamma d'agents actifs nanoparticulaires solides
AU2003297260A1 (en) * 2002-11-12 2004-06-03 Elan Pharma International Ltd. Fast-disintegrating solid dosage forms being not friable and comprising pullulan
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
CA2534924A1 (fr) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Nouvelles compositions de metaxalone
ES2366646T3 (es) * 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
US20050147664A1 (en) * 2003-11-13 2005-07-07 Elan Pharma International Ltd. Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
WO2006054314A1 (fr) * 2004-11-17 2006-05-26 Natco Pharma Limited Formes polymorphes de mesylate d'imatinibe
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤

Also Published As

Publication number Publication date
ES2341996T3 (es) 2010-06-30
ZA200710763B (en) 2009-09-30
EA015102B1 (ru) 2011-06-30
KR20080017067A (ko) 2008-02-25
ATE459341T1 (de) 2010-03-15
WO2006133046A2 (fr) 2006-12-14
WO2006133046A3 (fr) 2007-07-26
EP1895984B8 (fr) 2010-05-12
AU2006255177A1 (en) 2006-12-14
IL187841A0 (en) 2008-03-20
MX2007015309A (es) 2008-03-05
DE602006012671D1 (de) 2010-04-15
JP2008542397A (ja) 2008-11-27
EP1895984B1 (fr) 2010-03-03
HK1118467A1 (en) 2009-02-13
EA201100022A1 (ru) 2011-06-30
CN101232870A (zh) 2008-07-30
EP1895984A2 (fr) 2008-03-12
CA2610448A1 (fr) 2006-12-14
BRPI0613540A2 (pt) 2011-01-18
EA200702641A1 (ru) 2008-04-28
US20060275372A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
NO20076691L (no) Nanopartikulaere imatinib-mesylatformuleringer
CY1116902T1 (el) Παραγωγα ισοξαζολο-πυριδινης
NO20076692L (no) Nanopartikulaere acetaminofenformuleringer
TW200714604A (en) Substituted heterocycles and the uses thereof
NO20076215L (no) Nanopartikulaere clopidogrelformuleringer
JP2012526113A5 (fr)
ATE540944T1 (de) Pyridylpiperidinorexin-rezeptorantagonisten
TW200716573A (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CR11207A (es) Compuestos organicos
NO20073334L (no) Nanopartikulaert benzotiofenformuleringer
WO2008050199A8 (fr) Composés de phénylméthyl bicyclocarboxyamide substitués
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
GB0520751D0 (en) Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease
EA201001129A1 (ru) Пиримидины в качестве ингибиторов киназы
IL187966A0 (en) New azetidine derivatives as neurokinin receptor antagonists for the treatment of gastrointestinal diseases
GB0510584D0 (en) Organic compounds
ATE530188T1 (de) Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
MY153719A (en) Prokineticin 1 receptor antagonists
GB0524814D0 (en) Compounds
TW200745081A (en) Compounds
EP1899318A4 (fr) Nouveaux derives d'azetidine utiles en tant qu'antagonistes des recepteurs des neurokinines employes pour le traitement des maladies gastro-intestinales
DE602006010070D1 (de) Nanopartikuläre ebastinformulierungen
GB2442366A (en) Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
NO20074458L (no) N-hydroksamidderivater og anvendelse derav
DE602006017849D1 (de) 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application